Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyeloMATCH SubStudy in High-Risk AML
NCT05554406Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2024
- Primary completion
- Mar 2027
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of venetoclax, daunorubicin + cytarabine liposome and azacitidine in acute myeloid leukemia (AML) (5 arms), sponsored by National Cancer Institute. Primary endpoint: Minimal residual disease response at 56 days. Started Sep 2024; status: recruiting.
02
Drugs
venetoclaxdaunorubicin + cytarabine liposomeazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05554406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554406.